Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Novo reports first Ozempic sales drop in greater China region
02:18am, Thursday, 05'th Feb 2026
Sales of Novo Nordisk's blockbuster diabetes drug Ozempic in the greater China region fell for the first time last year, as it grapples with competition from rivals.
Market Today: Tech Slump, Google AI Spend, Bitcoin Slide
05:35pm, Wednesday, 04'th Feb 2026
Guru Stock PicksAzvalor Internacional FI has made the following transactions:Reduce in XMAD: PSG by 98.37%Sold out in BAAdd in XMAD: COL by 6.77%New position in A
Eli Lilly Stock Soars While Novo Nordisk Sinks—Why the Weight-Loss Leaders Are Headed in Opposite Directions
05:25pm, Wednesday, 04'th Feb 2026
There's a growing divergence between the shares of rival weight-loss drugmakers Eli Lilly and Novo Nordisk.
Novo Nordisk: A Game Of Price Vs. Volume
05:25pm, Wednesday, 04'th Feb 2026
Novo Nordisk A/S maintains a Buy rating despite recent share declines and challenging FY2026 guidance. NVO faces persistent pricing pressures, margin compression, and market share loss but is betting
Eli Lilly Stock Soars While Novo Nordisk Sinks—Why the Weight-Loss Leaders Are Headed in Opposite Directions
04:26pm, Wednesday, 04'th Feb 2026
There's a growing divergence between the shares of rival weight-loss drugmakers Eli Lilly and Novo Nordisk.
Novo Nordisk Plunges After Releasing a Brutal Forecast. Should You Dump the Stock?
02:55pm, Wednesday, 04'th Feb 2026
Novo Nordisk expects its sales to decline, on an adjusted basis, by between 5% and 13% this year. Pricing pressures and increased competition are weighing on its growth prospects.
Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026
02:51pm, Wednesday, 04'th Feb 2026
Both Novo Nordisk and Eli Lilly are grappling with pricing pressure in the U.S., but their 2026 outlooks are diverging sharply. While Novo is bracing for a sales decline, Lilly sees revenue charging a
Eli Lilly Soars, Novo Nordisk Plummets On GLP/Obesity Updates - Here's What To Do
02:26pm, Wednesday, 04'th Feb 2026
Eli Lilly and Company defies valuation skeptics, posting 45% revenue growth and 96% EPS growth in 2025, with 2026 guidance projecting $80–83 billion in revenue and $33.5–35 EPS. LLY's manufacturin
In Weight Loss Drug Battle For 2026, Eli Lilly Pulls Ahead Of Novo Nordisk
02:02pm, Wednesday, 04'th Feb 2026
Over the last two days, Novo Nordisk A/S (NYSE: NVO) stock has plunged around 18% after the company issued a softer outlook for fiscal 2026.
Novo Nordisk Q4: Slumping Due To Weak Guidance
12:38pm, Wednesday, 04'th Feb 2026
Novo Nordisk A/S shares dropped ~20% after issuing weaker-than-expected 2026 guidance despite strong 2025 obesity drug growth. NVO's 2025 revenue rose 10% at constant currency rates, but margin compre
Novo to launch Ozempic pill for diabetes in second quarter of this year
12:23pm, Wednesday, 04'th Feb 2026
Novo Nordisk said on Wednesday it will launch some doses of its oral semaglutide for diabetes under the brand name Ozempic pill in the second quarter of this year.
Eli Lilly's Strong Q4 Performance and Promising Outlook Propel Stock Higher
12:14pm, Wednesday, 04'th Feb 2026
Eli Lilly (LLY) delivered an impressive performance in Q4 2025, driving its stock higher as it continues to lead in the obesity and diabetes treatment markets.
Eli Lilly Guides Up to 27% Sales Growth as Obesity Demand Surges
12:10pm, Wednesday, 04'th Feb 2026
Eli Lilly (LLY) has laid out a notably stronger sales outlook for the year, signaling continued momentum in the weight-loss market as demand for its obesity tre
Novo Nordisk: My Certainties Swept Away By A Quarterly Report (Downgrade)
12:09pm, Wednesday, 04'th Feb 2026
Novo Nordisk A/S faces disappointing 2026 guidance, projecting a 5–13% revenue and operating profit decline despite Wegovy pill adoption. Margin pressure arises as the oral Wegovy pill is costlier t
Novo Nordisk Stock Sinks on Weak Sales Forecast
10:55am, Wednesday, 04'th Feb 2026
Novo Nordisk A/S (NYSE:NVO) stock is extending last session's 14.6% slide, down 3.7% to trade at $48.44 at last glance.
